VERA实时信号 | 通过Getagraph.com最大化利润

出售 7116 min ago

@ $39.35

发出时间: 25 Apr 2024 @ 01:31

回报率: 5.24%

上一信号: Apr 24 - 02:31

上一信号: 购买

回报率: -1.87 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:07):

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States...

Stats
今日成交量	254 901
平均成交量	1.13M
市值	2.27B
EPS	$0 ( 2024-03-26 )
下一个收益日期	( $-0.530 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-18.40
ATR14	$0.117 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Young Joseph R	Sell	5 714	Class A Common Stock
2024-04-03	Grant Sean	Buy	99 828	Class A Common Stock
2024-04-03	Grant Sean	Sell	69 831	Class A Common Stock
2024-04-03	Grant Sean	Sell	10 988	Class A Common Stock
2024-04-03	Grant Sean	Sell	99 828	Stock Option (right to buy)

INSIDER POWER
32.66
Last 98 transactions
Buy: 7 469 518 \| Sell: 2 159 720

音量相关性

長: 0.03 (neutral)

短: -0.03 (neutral)

Signal:(48.951) Neutral

Vera Therapeutics, Inc. 相关性

10 最正相关
LCAP	0.928
VTIP	0.912
CYTO	0.907
PAIC	0.896
MTEX	0.892
GAINL	0.889
RMRM	0.886
PROC	0.886
WNW	0.884
OP	0.873

10 最负相关
SCR	-0.952
BOCH	-0.924
NETE	-0.919
KIN	-0.914
SHSP	-0.904
IPHA	-0.899
DGLY	-0.898
SRRA	-0.898
THCPU	-0.898
ICON	-0.895

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Vera Therapeutics, Inc. 相关性 - 货币/商品

-0.08
( neutral )

-0.17
( neutral )

0.00
( neutral )

0.32
( neutral )

0.30
( neutral )

0.52
( weak )

Vera Therapeutics, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$1.86M (0.00 %)
EPS:	$-2.25

FY	2023
营收:	$0
毛利润:	$1.86M (0.00 %)
EPS:	$-2.25

FY	2022
营收:	$0
毛利润:	$846 000 (0.00 %)
EPS:	$-3.35

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-8.00

Financial Reports:

No articles found.

Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.